The clinical utility of most analgesic drugs is altered in the presence of patients with impaired renal or hepatic function not simply because of altered clearance of the parent drug, but also through production and accumulation of toxic or therapeutically active metabolites. Some analgesic agents may also aggravate pre-existing renal and hepatic disease.
The clinical utility of most analgesic drugs is altered in the presence of impaired renal or hepatic function: this is not simply because of variations in clearance of the parent drug, but also due to potential production and accumulation of toxic or therapeutically active metabolites. In some cases, analgesic agents may aggravate pre-existing renal and hepatic impairment; consequently modifying their own metabolism.
To assist in the provision of guidelines for the pharmacologic management of acute pain in these situations, a literature review was performed, searching for data on altered dosing requirements, adverse reactions and the mechanisms responsible. Categorization using evidence-based medicine principles was planned, to give appropriate weighting to the consequent findings and recommendations.
With increased understanding of the mechanisms which induce and maintain the pain state, drugs not traditionally used for pain relief have been incorporated into the analgesic armamentarium. These were included in the search criteria, and consist of some antiepileptic and antidepressant medications, mexiletine, alpha-2 agonist drugs and the anaesthetic drug ketamine. They are more commonly used in the treatment of neuropathic pain, although the latter two may also be used for nociceptive pain management.
METHODS
A Medline search was performed using the following key words: acetaminophen, alfentanil, amitriptyline, analgesia, aspirin, bupivacaine, buprenorphine, carbamazepine, clonidine, codeine, dextropropoxyphene, diclofenac, dihydrocodeine, epilim, fentanyl, gabapentin, hydromorphone, ketamine, ketorolac, levobupivacaine, lignocaine, meperidine, methadone, mexiletine, morphine, naltrexone, nsaid, oxycodone, paracetamol, pethidine, propacetamol, remifentanil, ropivacaine, sufentanil, tramadol, tricyclic antidepressant, and valproate. The results were then linked in a combined search with each of the following: "renal failure", "renal function", "hepatic failure" and "hepatic function". The resultant abstracts were reviewed for relevance and those which did not address the issues of altered dose requirements or adverse reactions or the mechanisms responsible for these were excluded. Only those articles with an English text body were then obtained.
Published pharmacokinetic data and pharmaceutical company monographs were sought for the drugs listed above.
The following pharmacology texts were consulted: • Drug Monitoring Data -Pocket Guide II-2nd Edition. American Association for Clinical Chemistry, Inc., Washington DC, 1994 43 . • Therapeutic Guidelines: Analgesic (Victorian Drug Usage Advisory Committee)-3rd Edition. Therapeutic Guidelines Limited, Victorian Drug Usage Advisory Committee, Melbourne, Vic., Australia, 1997 14 Aside from the above texts, around 70 articles were reviewed in depth, and some articles were excluded because they added no new data to larger scale studies or reviews.
FINDINGS
The words "dysfunction", "failure", "impairment" and "insufficiency" appear to be used interchangeably throughout the literature, but will be quantified by degree where possible.
Using evidence-based medicine definitions 1 , the best available data consisted of small group nonrandomized pharmacokinetic studies, some with a control group of patients displaying normal organ function: this constitutes level III evidence. Some data comprised small group patient case series with drug or effect assessment; constituting level IV evidence. A major portion of the data however, involved single case studies, or expert opinion based upon pharmacological properties of the analgesic agents, which is no longer considered truly evidence based 1 : It is however, the only guidance available for some pharmacologic agents in this setting. The phrase "use with caution" is encountered frequently in referenced articles without further clarification; in the context of this article the author would suggest that it should at least imply dose titration with observance for and avoidance of toxic or excessive therapeutic effect, and an understanding of the effects of organ dysfunction on drug metabolism.
The available evidence levels and recommendations are considered separately for each drug class, with discussion of both alterations in therapeutic effect, and potential toxic effects. In all cases where a drug's half-life is prolonged, the resultant delay in achieving a steady state concentration must be considered whilst observing for these effects.
OPIOIDS
Considerable pharmacological variation occurs within this group. The majority of biotransformation is liver-dependant, including that for the short acting agents. Minimal evidence exists to guide the appropriate use of opioids in the presence of hepatic failure. Titration to effect should be more cautious than usual with all opioids in the presence of liver failure 2 . A small number of case reports link opioid usage with acute renal failure, reversible with naloxone 3, 4 , however this is not borne out in the literature as a common problem, and no explanation for the underlying mechanism was given, excepting animal data linking opioid dosage with an increase in vasopressin levels.
Alfentanil
A controlled pharmacokinetic study assessing patients with end stage renal failure found an increase in the unbound plasma fraction of this drug due to alterations in protein binding, but no change in plasma clearance, which occurs primarily through hepatic metabolism 2,5 (Level III evidence for both references). Under these conditions there may be a decreased dosage requirement, but no change in the required dosing intervals, as the drug does not have significant active metabolites 2 .
In a study assessing 9 children with cholestatic liver disease and 10 children with chronic renal failure undergoing organ transplantation, no significant difference was found in alfentanil clearance or half-life 6 (Level III evidence), suggesting the drug is safe to use in these groups. by primary biliary excretion. Metabolite levels are increased four-fold in the presence of renal failure, but this is unlikely to have clinical consequences. It may be given in standard doses in the presence of renal failure 2 (Level III evidence). No evidence was found to guide treatment in the presence of hepatic dysfunction.
Codeine
Approximately 10% of codeine is metabolised to morphine, which provides the majority of its clinical effect. Most ingested codeine is converted to codeine-6-glucuronide which is then renally excreted. Although many opioids have been associated with central nervous system (CNS) excitation and seizures at higher doses, codeine appears to have a lower therapeutic ratio, and may cause these effects when the standard daily dose is exceeded 7 . It has been reported to cause prolonged sedation in the presence of renal failure, with a beta half-life of up to 27 hours in dialysis dependant patients 2 (Level III evidence). The available evidence does not support clinical use in the presence of renal or hepatic failure.
Dextropropoxyphene
Plasma concentrations of both dextropropoxyphene and nordextropropoxyphene, its major metabolite, are significantly increased with renal failure, and the half-life of the metabolite is prolonged 2 . The potential consequences of this include CNS, respiratory and cardiac depression 2 . It has been associated with a number of deaths, many quite rapid, in cases of both accidental and intentional overdosage 8 . Animal studies found intracardiac conduction delays in the presence of overdosage due to both the parent drug and its metabolite 2 . It is inefficiently cleared during dialysis, and its use is not recommended in the presence of renal failure 2 .
It is subject to considerable first pass hepatic metabolism after absorption, and has been associated with impairment of liver function 8 . No studies were located which specifically assessed safe usage in the presence of hepatic failure.
Dihydrocodeine
This probably has similar elimination to codeine, and has been reported to cause prolonged sedation, reversible with naloxone 2 . It has not been so intensively studied however, and should be avoided in the presence of renal failure.
No evidence was found to guide treatment in the presence of hepatic dysfunction.
Fentanyl
Fentanyl is subject to a high hepatic extraction ratio, which may lead to decreased clearance values in the presence of altered hepatic blood flow during uraemia. The pharmacokinetics of fentanyl have been studied in eight patients with end stage renal failure undergoing renal transplantation after a loading dose of 25 µg/kg, and a strong correlation existed between clearance and blood urea nitrogen levels. The most marked changes in clearance occurred when urea levels were greater than twice the normal value 9 (Level IV evidence). Fentanyl has no active metabolites and has been shown in some pharmacokinetic studies to have no significant change in clinical effects, with normal clearance values in the presence of chronic renal failure. It does have a prolonged clearance (half-life up to 25 hours) in the critically ill patient which must be taken into consideration 2 . It does not appear to have been studied extensively in the paediatric population with organ failure, however a single article reported normal pharmacokinetic values in one child with renal failure given high-dose fentanyl anaesthesia, but markedly impaired clearance (1/20 normal) in a child who underwent hepatic manipulation during surgery 10 . Considering the lack of active metabolites, fentanyl is an ideal agent for use in renal failure; with the provision that high levels of uraemia may significantly prolong clearance and require a decrease in dosage. (The available data suggests 1/2 to 1/3 of usual commencement doses may be required in this case.)
Hepatic failure is likely to impair fentanyl clearance and require a dosage reduction, however no data was found to guide this specifically.
Hydromorphone
Hydromorphone is a semi-synthetic derivative of morphine, metabolized in part to hydromorphone-3glucuronide (H3G), which is present at a steady state concentration approximately 27 times that of the parent drug in normal patients. H3G has been shown to accumulate in the presence of renal failure to a level approximately four times higher. It is postulated as the cause for neuroexcitation and cognitive impairment which has been reported with this drug in the presence of renal failure, and is a reason to consider an alternative agent if these symptoms should occur 11 . One retrospective study compared hydromorphone use in 55 palliative care patients with either normal or impaired renal function, who were switched to this drug from other opioids (mostly morphine) because of adverse reactions. There was no significant difference in opioid conversion factors between groups and a lower incidence of unwanted side-effects. Whilst the median doses were higher in the normal group, the mean doses were not significantly different between groups. This study suggests that hydromorphone use may be safe in the presence of renal failure, and is associated with a lower incidence of side effects than morphine in this group 12 (Level III evidence).
The drug undergoes a high first pass metabolism 13 , and will be subject to increased bioavailability in the presence of hepatic impairment. No evidence was found to guide safe use of the drug in this scenario.
Methadone
The drug has a long half-life and is therefore not suitable for the initial management of acute pain 14 . It has a high oral bioavailability of around 80% of the ingested dose. Renal excretion of the unchanged drug accounts for approximately 20% of the total dose 2 , whilst the majority of clearance occurs through the gastrointestinal tract after hepatic transformation to predominantly inactive metabolites 15 . A case report of two patients with renal failure showed serum methadone levels in the range expected with normal renal function, however it is generally recommended that lower starting doses be used when initiating therapy for the patient with renal failure, with subsequent doses titrated to effect 2 . It is contraindicated in the presence of severe liver disease 14 .
Morphine
The parent drug has been shown to undergo normal biotransformation in the presence of renal failure 16 (Level III evidence), however the clearance of one of the active primary metabolites morphine-6glucuronide (M6G) is highly renal dependant, and its consequent accumulation may cause a prolonged clinical effect. The half-life of M6G is prolonged from a normal value of 2.1 hours, up to as much as 27 hours in end stage renal failure. The other major metabolite, Morphine-3-glucuronide (M3G) also accumulates with renal failure 2 (Level III evidence): it is associated with antinociception and irritability, but has not been reported as a frequent cause of side-effects in the patient with renal failure: it may decrease the seizure threshold however, so morphine should probably be avoided where epilepsy and renal failure co-exist.
As M3G and M6G are products of morphine breakdown, it must be remembered that equivalent oral doses of morphine which are higher than parenterally administered morphine, will produce a greater metabolite load 17, 18 (Level III evidence in  reference 17 ). This should be considered as an additional risk factor when converting to oral morphine and necessitates a reduction in equivalence dosing by a factor of up to three, or the use of an alternative agent with inactive metabolites.
A wide variation in susceptibility to M6G effects may occur in the patient with renal failure. At least two causes for this have been determined. Firstly, up to 20% of patients may have decreased sensitivity to M6G due to genetic variation in the µ-opioid receptor: these patients could feasibly tolerate standard morphine dosage regimens, despite metabolite accumulation: only minimal clinical evidence of this has been reported 19 . A second cause for variation is known to exist in which active transport (efflux) of M6G across the blood brain barrier may be modulated via p-glycoprotein, which has been described as sensitive to modulation (decreased efflux) by verapamil and amitriptyline. (Other drugs may also cause this effect) 19, 20 . Both these variations can not be predicted clinically at present.
The time to onset of M6G effects may be quite prolonged as it is slow in traversing the blood brain barrier. In a controlled trial comparing eight normal patients with six end stage renal failure patients, peak morphine cerebrospinal fluid (CSF) morphine levels were similar between groups, but CSF M6G levels peaked at 12 hours in normal patients, and continued to rise to a 24 hour peak (at which time measurements were ceased) in those with end stage renal failure. The peak level was approximately 15 times that of the normal group, with the consequent risk of delayed sedation 17 (Level III evidence). Delayed sedation causing unconsciousness despite absence of elevated morphine levels has been reported following high loading doses in patients with renal failure. In one (adult) case the metabolite load resulted in prolonged sedation with initial onset time 26 hours after M6G blood levels approached their peak. At the onset of unconsciousness, plasma morphine levels were below the limit of quantification 21 . A similar case scenario has been reported in a child with renal failure using morphine patient-controlled analgesia, although M6G levels were not documented in this case 22 .
Whilst morphine and its metabolites are usefully removed during haemofiltration (47-100%) and haemodialysis (24-84%) 2 , they are not significantly cleared by continuous ambulatory peritoneal dialysis, which has similar clearance values to end stage renal failure 20, 23 (Level III evidence in both references).
On the basis of widespread clinical use and avail-able evidence, morphine appears to be a safe agent to use in the presence of renal failure, provided it is carefully titrated to effect, and provided it is not continued where large doses are likely to be required with acute pain. In the situation where high initial doses are required, there is a significant risk that high metabolite levels will lead to delayed sedation as the pain abates. In this scenario, ongoing analgesia should be altered to a shorter acting drug or one without active metabolites such as fentanyl or oxycodone until analgesic requirements decrease to a lower, steady state. If parenteral morphine doses are converted for oral administration in the presence of renal failure, then the likelihood of a significant increase in metabolite load due to first pass metabolism must be considered, and doses appropriately lowered. Morphine use in hepatic failure does not appear to have been usefully studied. Reported hazards include precipitation of hepatic encephalopathy, increased oral bioavailability of morphine due to its normal high first pass metabolism when given via this route 24 , and impaired clearance.
Oxycodone
Oxycodone is eliminated mainly through hepatic metabolism to noroxycodone and oxymorphone, and some effect has been attributed to metabolite activity. One controlled study compared 10 normal patients with 10 uraemic patients who underwent cadaver renal transplants, after a single loading dose of oxycodone. None of the transplanted patients had immediate graft function, and in all cases the oxycodone half-life was significantly prolonged. The median half-life increased by a factor of 1.7, although individual variation within the transplant group was significant, with values up to 10 times normal. Oxycodone has a lower hepatic clearance than morphine, and it was considered that some of the variation in the latter group may be accounted for by alterations in hepatic blood flow with uraemia, or the use of calcium channel blockers which are known to reduce hepatic blood flow and enzyme activity 25 (Level III evidence). With this in mind, oxycodone should be cautiously titrated to effect in the presence of renal failure.
Pethidine
Pethidine (known also as meperidine) is primarily cleared by hepatic demethylation to norpethidine, its sole active metabolite 2 . Norpethidine has a usual half life of 14 to 21 hours 2 , but this is prolonged in the presence of renal failure 2, 26, 27 to around 35 hours 2 , The accumulation of this metabolite has been associated with seizures and death 2 . In patients with normal renal function, toxicity will occur in approximately 19 per cent of cases where doses exceed around 10 mg/kg/day or therapy exceeds three days duration 27 (Level III evidence). The toxic dose will obviously be much lower in the presence of renal failure, and safe doses have not been determined. A single dose in the presence of renal failure is unlikely to produce clinically significant toxicity 2 , however its use is not recommended in the presence of renal failure 2, 26, 27 , and with the existence of better alternatives its use should now be contraindicated in this situation. Its use during dialysis does not appear to have been studied. Pethidine has not been studied in the presence of hepatic failure, but there is no basis on which to recommend its use above other agents without toxic metabolites.
Remifentanil
This drug undergoes blood esterase hydrolysis to a minimally active metabolite. It has been shown in pharmacokinetic and clinical effect studies in patients with renal failure 2,28,29 (Level III evidence in references 28 and 29), hepatic cirrhosis, mild hepatic encephalopathy 30 , and during the anhepatic phase of liver transplantation 31 (Level III evidence) to have no significant change in clinical effects compared with published normal subject data, and slight, statistically significant changes in serum levels. One study titrating to haemodynamic response under general anaesthesia required a mean reduction to 2/3 of the control group infusion rate in the presence of renal failure 29 (Level III evidence). It represents the ideal opioid for use in both renal and hepatic failure when used within an appropriate clinical setting, which must include regular assessment of sedation levels and respiratory function, with a reliable infusion device, and a skilled clinician with training in the safe use of this potent opioid. It is not appropriate for use outside of a high dependency clinical setting.
Sufentanil
This drug has no active metabolites, and is not generally expected to require dose adjustment in the presence of renal failure 14 . Clearance and half-life were more variable than normal in adolescents with chronic renal failure, despite a lack of statistical difference 32 (Level III evidence), and there has been a case report of unexpected prolonged sedation in a patient with renal failure, so it should be used with caution 2 . In patients with uncomplicated cirrhosis under anaesthesia, loading doses of 3 µg/kg were not associated with significant differences in plasma clearance or elimination half-life over 10 hours of measurement 33 (Level III evidence).
Tramadol
Tramadol is primarily metabolized in the liver to substances including the only pharmacologically active metabolite; O-desmethyltramadol (M1), which contributes toward its analgesic effect. Both the parent drug and its metabolites undergo primarily renal excretion, and hence are subject to accumulation in the presence of renal failure 34 . It has not been implicated in the production of renal impairment in man, and one animal study assessing renal blood flow in rats found no alteration in those with normal kidneys, nor those with experimentally induced nephritis, despite an increase in systemic blood pressure 35 (Level III evidence).
The product manufacturers' literature recommends that dosage intervals should be increased to every 12 hours where creatinine clearance is less than 30 ml/min (24 hours for slow release formulation), and that the drug should be avoided where creatinine clearance is less than 10 ml/min 34 . This recommendation for twelve hourly dosing is impractical for treating acute pain as it ignores the need for a loading dose. No evidence was found to guide appropriate loading in this circumstance, however if used in the absence of such guidelines' it would be prudent to titrate the drug cautiously and cease dosing if agitation, hyperreflexia, myoclonus or other signs of serotonergic syndrome occur.
In the presence of severe hepatic insufficiency where its use is contemplated, only the 50 mg immediate release formulation should be used, with cautious titration to clinical effect. Dosage intervals will need to be extended, and the patient should be observed for signs of serotonergic syndrome; if these occur the drug should be ceased, and the syndrome appropriately managed as per product guidelines 34 .
ALPHA-2 AGONISTS Clonidine
Clonidine has been utilised as an anti-hypertensive agent in patients with renal failure at doses of up to 600 µg orally or transdermally daily. No deterioration in renal function occurred, and no unusual sideeffects were documented. The half-life was increased from a normal value of 12 hours up to 40 hours with severe renal failure 36 . The drug is normally less than 50% metabolized by the liver, with the remainder excreted unchanged in urine 37 . It should be given at a reduced dose in the presence of renal failure.
Dexmedetomidine
As a new agent, dexmedetomidine has not been widely studied in the context of acute pain management, although it is approved for the provision of combined analgesia and sedation within the intensive care setting. It undergoes extensive hepatic metabolism to an inactive metabolite and may prove suitable for use in the presence of renal failure.
No evidence was found to guide the use of either drug in the presence of hepatic dysfunction.
TRICYCLIC ANTIDEPRESSANTS
This drug class undergoes primarily hepatic metabolism. Amitriptyline is most commonly used, and undergoes conversion in the liver to nortriptyline, the active agent. The doses used to assist with management of neuropathic pain are generally less than those used to treat depression, however the articles which assessed use in renal failure all considered the latter, higher doses. There is little indication for dose reduction in renal failure 38, 39 (Level III evidence in both references), however, it has been suggested that metabolite accumulation may increase the likelihood of unwanted side-effects 38 .
Both amitriptyline (2-10% incidence of elevated liver function tests) and nortriptyline have been associated with acute fulminant hepatic failure, but the mechanism remains uncertain 40 . They both require ongoing monitoring to exclude abnormalities in liver function during introduction, in which case the drug should be discontinued.
LOCAL ANAESTHETICS
The amide type local anaesthetics which include bupivacaine, levobupivacaine, lignocaine and ropivacaine, undergo primarily liver metabolism to inactive metabolites prior to excretion. The local anaesthetic procaine has an ester linkage which also allows hydrolysis by plasma cholinesterase. Toxic levels of local anaesthetics are calculated on the basis of steady state concentrations during short intravenous infusion 41 , however the systemic absorption rate associated with various routes of administering these drugs is quite variable 42 . In general all local anaesthetics will be subject to decreased clearance with hepatic failure, and may be associated with a higher risk of side-effects in the presence of renal failure due to altered protein binding and volume of distribution.
One study looked at eleven patients given bilateral intercostal nerve blocks following hepatic transplant, to assess the effects of bupivacaine 2 mg/kg in this group. A total of twelve blocks were performed, and six of these gave rise to toxic threshold levels of 2 to 4 µg/ml bupivacaine, but no detectable clinical effects. In those patients whose results were displayed in graphic form, the elimination half life was six hours: approximately double the normal value 41 (Level IV evidence). In the absence of further studies to assess safety with other causes of hepatic failure, these results indicate the need to avoid using analgesic techniques which require large doses of bupivacaine to obtain spread of the drug, as plasma clearance following redistribution from the effect site will not have occurred in time for further dosing. The maximum daily dose should be at least halved. Using the figures supplied by the Australian Medicines Handbook, this would indicate a maximum adult dose of 200 mg/day.
Lignocaine has previously been shown to have impaired clearance in patients with hepatic disease 43 , after hepatectomy, and with viral hepatitis 41 . No quantitative dosage alterations were determined, however it would be prudent to assume that adrenaline will have less of a protective effect for larger single doses due to the prolonged half-life, and that the lower dose range should be used cautiously in patients with hepatic impairment, observing regularly 
Opioid pharmacology with renal or hepatic dysfunction: Summarised findings

Opioid agent
Potential effects due to metabolite. Recommendations for use in the Reported use in the presence of Accumulation in the presence of presence of renal dysfunction. hepatic dysfunction. renal dysfunction.
Alfentanil
Nil significant metabolites 2 . Dose reduction required 2, 5 .
Unchanged clearance in children with cholestatic disease 6 .
Buprenorphine
Nil significant metabolites 2 . Standard doses may be used 2 .
Nil.
Codeine
Neuro-excitation may occur at Not recommended on basis of Nil. standard doses 7 . Morphine available evidence 2 . metabolite accumulation increases sedation risk.
Dextropropoxyphene
Cardiac and hepatic toxicity 2, 8 . Not recommended on basis of Nil. available evidence 2 .
Dihydrocodeine
Unknown, probably similar to Not recommended due to Nil. codeine 2 .
insufficient evidence of safety 2 .
Fentanyl
Nil significant metabolites 2 . May require dose reduction 2, 9 . Case report of greatly impaired clearance after hepatic manipulation 10 .
Hydromorphone
Neuro-excitation and delayed Dose reduction required 12 .
Nil. Higher bioavailability likely 13 . sedation possible 11 .
Methadone
Nil significant metabolites 15 . Not recommended for initial Cautious use with mild degrees of treatment due to long half-life 14 .
liver dysfunction reported 2 .
Morphine
Delayed sedation from M6G with Dose reduction required. Choose Precipitation of hepatic renal failure, especially when using an alternative agent if high encephalopathy reported 24 , also high initial doses 2 . Neuro-excitation doses likely to be used. increased oral bioavailability. from M3G 2 . Higher metabolite load with oral dosing 17, 18 .
Oxycodone
Increased opioid effects due to less Dose reduction required with Nil. active metabolites, which have uraemia 25 . impaired excretion 25 .
Pethidine
Neuro-excitation and seizures due Not recommended (single dose Nil. to norpethidine accumulation 2, 26, 27 .
probably safe) 2 .
Remifentanil
Nil significant metabolites 2,28 . May require slight dose reduction 29 . Case report of safe use. Suggested need for dose reduction 30 .
Sufentanil
Nil significant metabolites 14 . Dose reduction may be required 2,32 . 3 µg/kg loading reported safe with uncomplicated cirrhosis 33 .
Tramadol
Increased tramadol-like effects Dose reduction required. Avoid Nil. Manufacturer's literature from O-desmethyltramadol (M1) 34 .
where creatinine clearance suggests safety with mild degrees <10 ml/min 34 . of dysfunction using reduced doses.
for signs of toxicity during infusion or injection. Lignocaine also gives rise to some active metabolites which will be less rapidly cleared in the presence of renal failure, and may increase the risk of toxicity with prolonged infusions 44 .
One study assessed the use of 0.5% levobupivacaine for axillary block in eight patients with end stage renal disease, and compared clinical outcomes and pharmacokinetic values with eleven patients who had normal renal function. Following a dose of 50 to 60 ml of the solution, there was no significant difference between groups for clearance of the drug or clinical outcome 45 (Level III evidence). As bupivacaine has a greater cardiac toxicity than both ropivacaine and levobupivacaine, but similar metabolism and duration of action 46, 47 , these latter two are probably more suitable for use in the presence of renal or hepatic failure if larger doses are required. All local anaesthetic agents should however be used cautiously where either problem exists. Those regional anaesthesia techniques which use lower drug doses such as spinal anaesthesia would theoretically be safer, but no comparative study was located using the search strategies outlined.
Mexiletine
This drug undergoes extensive hepatic metabolism, but is also excreted by up to 15% unchanged in the urine. It has been used in the acute setting for treatment of refractory neuropathic pain in patients who have responded to intravenous lignocaine, with which it has structural similarities. It has a significant antiarrhythmic effect, and hepatic impairment will increase the risk of toxicity 48 . It is not recommended in this situation unless other treatment modalities have been exhausted, and the potential risks taken into account. Plasma concentrations should then be monitored to allow dose titration 49 .
It has been shown to have normal clearance in patients with renal failure where the creatinine clearance exceeds 10 ml/min 50 (Level IV evidence), and unchanged plasma levels in dialysis dependant patients given 600 mg/day 49 (Level III evidence). In the absence of large controlled trials, the lowest effective dose should be used.
KETAMINE
Ketamine use in acute pain management involves the use of low infused doses (between 0.06 and 0.24 mg/kg/h) to minimize the incidence of hallucinations and dysphoria 51 , and to prevent unintentional loss of consciousness. Bolus dosing of 1 to 1.5 mg/kg intravenously has been recommended 52 prior to painful procedures, but this dose range is capable of inducing general anaesthesia in some patients and is only appropriate in the fasted patient under safe conditions for providing general anaesthesia. A pharmacokinetic study of four patient groups receiving ketamine 1.1 to 1.3 mg/kg/h for long-term analgesia and sedation within an intensive care unit did not show a significant increase in ketamine levels in patients with cardiogenic shock or acute renal failure (Level III evidence), (a 20% increase in this group did not reach statistical significance). The renal failure group had significantly higher dehydronorketamine metabolite levels, however this was only by a factor of five, and it has but one hundredth the potency of ketamine. Less than 10% of the delivered dose of ketamine was removed during haemodialysis or haemofiltration. Animal studies found the drug to undergo mostly hepatic elimination, and did not show evidence of renal blood flow alteration 53 . The search parameters did not uncover any studies using the lower range analgesic doses, but the above values for higher infusion rates indicate that a dose adjustment is unnecessary in the presence of renal failure.
No data was found to guide the appropriate use of low dose ketamine in the presence of hepatic failure.
ANTI-EPILEPTICS
These may be considered during the acute setting as an adjunct in the treatment of neuropathic pain. Those used are carbamazepine, valproate, and gabapentin. Combination therapy using more than one of these agents is not recommended for acute pain management, as pharmacokinetic interactions may occur in an unpredictable fashion 54 , and the risk of fatal hepatotoxicity from valproate is increased in this situation 55 . Gabapentin is probably the safest agent in the presence of either renal failure or hepatic failure.
Carbamazepine
This drug has been reported to cause acute hepatic failure rarely (around 1/30,000 cases) in children, and elevation of hepatic enzymes (approximately 6% of patients treated) 56 . It is also an inducer of hepatic enzymes. The drug undergoes primarily hepatic metabolism, with less than 1% excreted renally, and is contraindicated in severe hepatic impairment 54 . It has also been reported as causing reversible acute renal failure, although this is rare 57, 58 . Its use in the acute setting should be associated with regular monitoring of hepatic and renal function to allow discontinuation if these should deteriorate.
Valproate
Fatal hepatic failure may occur due to valproate treatment: pathological data suggests that some cases are the result of chronic liver damage and cirrhosis 59 . This rare complication has an incidence of between 1/10,000-49,000 in adults 59, 60 , but may be significantly increased with the combination of antiepileptic medications, due to diversion of metabolism toward toxic pathways. The initial presentation may include anorexia, abdominal discomfort, nausea and vomiting, prior to depressed consciousness in association with biochemical markers of hepatic injury 61 . The complication is more common in children, and was reported in association with 21 childhood deaths from hepatic failure in the United Kingdom prior to the year 2000 62 . Abnormalities of liver function occur in up to 44% of patients 60 : and may include elevated transaminases and impaired coagulation 63 . There is some evidence that this complication is associated with impaired beta-oxidation of the drug. Aspirin also interferes with beta-oxidation and should not be used concurrently. Valproate should be avoided in patients with known liver disease 61 . If used in the presence of renal failure, decreased albumin levels may lead to an increase in unbound serum levels, and doses should be lowered 64 . Plasma levels of the drug may be monitored to assess the potential for toxicity.
Gabapentin
Gabapentin undergoes primarily renal excretion in unchanged form, and has an approximate elimination half life of 132 hours in dialysis dependant patients. The half life during haemodialysis is around four hours, with a recommendation to replace losses by 200-300 mg for every four hours of this 65 (Level IV evidence). It otherwise requires dose reduction with renal failure according to creatinine clearance, in line with published guidelines 54 .
This drug was not found to be associated with hepatic failure under the search conditions indicated, and is probably the safest choice in this class in the presence of hepatic failure. It must be remembered that this is a relatively new drug, and some unexpected adverse effects may not yet have been elucidated.
NON STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) AND COX-2 SPECIFIC INHIBITORS
This class are traditionally associated with the risk of precipitating acute renal failure due to inhibition of prostaglandin production, and consequent renal afferent arterial vasoconstriction with the potential to reduce glomerular filtration rate. In most cases this is reversible, and is associated more frequently with dehydration, hypotension, pre-existing renal failure, liver cirrhosis and excessive dosage 66, 67 . There is only limited evidence suggesting a causal association with chronic renal failure 68 . Some studies have found no significant effect in patients with normal renal function, but there appears to be a small risk of idiosyncratic reaction, even in this group 67 . The onset of acute renal failure due to this class of drug is usually associated with oliguria and increased serum urea, creatinine and potassium levels 67 , which necessitates cessation of the agent responsible.
There is no strong evidence that any one NSAID is safer in terms of renal side-effects when equipotent doses are used. The newer COX-2 specific inhibitors, despite having lesser gastrointestinal and haematological effects, are pharmacodynamically similar in their effects on the renal vascular bed, and have similar renal side-effects [69] [70] [71] . The use of NSAIDs, aspirin or COX-2 specific inhibitors for analgesia should be avoided in the presence of chronic renal failure, due to the likely impairment of potassium handling, and the increased risk of acute renal failure or bleeding 71, 72 . If no alternative exists, then dosages must be kept to a minimum, hypotension and hypovolaemia prevented, and renal function monitored to allow cessation should deterioration occur: The first few days of treatment are associated with the highest risk, and creatinine clearance is a more sensitive measure of impairment than serum creatinine level 68 .
Elevated liver function tests have been reported in up to 15% of patients taking NSAIDs, and should lead to cessation of the drug if they occur 71 . Patients using the drugs parecoxib, rofecoxib or celecoxib with intercurrent moderate hepatic impairment were studied, and experienced elevated steady state drug levels, leading to a recommendation for decreased dosage in this subgroup [69] [70] [71] . No study assessed use in severe degrees of hepatic insufficiency. In all cases of hepatic insufficiency where NSAIDS are considered, regular monitoring of liver function should occur to allow cessation in the event of deterioration.
Ketorolac
Ketorolac is subject to extensive hepatic metabolism prior to renal excretion. The potential for renal toxicity has been extensively studied following a significant association with acute renal failure on its introduction. The recommended dose ranges have since been decreased, and it is not recommended for use beyond five days. One study retrospectively reviewed 198 healthy patients following donor nephrectomy, of whom 83 received ketorolac, with a mean total dose of 200 mg. The preoperatively calcu-lated creatinine clearance was equal to the group who did not receive ketorolac, but the postoperative values showed a slight decrease in clearance on the second postoperative day. There was no subgroup of patients who showed an association with renal function and the amount of ketorolac given, and there was no difference in creatinine clearance between normal and treated groups after three months from the time of surgery 66 (Level III evidence) . The relevance of this study is questionable as these patients may be assumed to have significant renal reserve on the basis of their suitability for kidney donation.
In the presence of mild renal impairment (creatinine clearance 20 to 50 ml/min), the half-life is approximately doubled: some authors suggest usage in this group, with dosage reduction to less than 60 mg/day. It should be avoided in patients with a greater degree of renal failure. In the presence of liver cirrhosis, clearance is slightly prolonged and the risk of renal dysfunction is also higher 67 , so dosage reduction is also necessary.
PARACETAMOL
Paracetamol (known also as acetaminophen) has been implicated in analgesic nephropathy: however the problem is statistically likely only in the case of prolonged use of compound analgesics containing at least two antipyretic agents along with caffeine or codeine. The resultant nephropathy has been linked to the synergistic effect of inhibition of prostaglandin synthesis and glutathione depletion in this situation 68 . In a study on nine patients with chronic stable renal failure using 40 mg/kg/day for three days, it did not alter renal glomerular or tubular function, however sulphate and glucuronide metabolites accumulated 73 (Level III evidence), Paracetamol is associated with less risk of acute renal failure than NSAIDS 72 or COX-2 inhibitors 74 , and is the simple analgesic of first choice in the patient with renal dysfunction. It may accumulate in uraemic patients due to effects on hepatic blood flow, but this was not addressed in any of the studies found: in this situation it would be wise to limit doses to the above figure of 40 mg/kg/day, and monitor hepatic function frequently during initiation of therapy.
Hepatic toxicity is a known consequence of paracetamol overdose, due to the formation of a reactive intermediate which binds to hepatocytes and causes tissue necrosis: this is protected against by endogenous glutathione, unless tissue stores become depleted. Liver enzyme inducers such as alcohol or barbiturates may increase the risk for toxic metabolite formation, and in the presence of hepatic cirrhosis, the prolongation of paracetamol clearance which occurs renders the patient more susceptible to toxic effects. In the presence of cirrhosis, drug dosage should be reduced 75 , although in the presence of moderate to severe liver failure, it should be avoided altogether.
RECOMMENDATIONS
The wide difference in degree of renal and hepatic impairment which exists, coupled with the proportionally small population group affected, has determined that most drugs are not studied extensively in this group prior to introduction. Small group pharmacokinetic studies and case reports cannot conclusively guide drug use for all degrees of organ failure. It remains up to the clinician in these cases to consider fully the risk/benefit equation for any drug introduced, in conjunction with other factors such as potential adverse reactions and known pharmacodynamic or pharmacokinetic interactions.
In consideration of the available data on patients with renal failure, the following statements may be made:
• Those drugs which exhibit the safest pharmacological profile are alfentanil, buprenorphine, fentanyl, ketamine, paracetamol (except with compound analgesics), remifentanil and sufentanil: none of these delivers a high active metabolite load, or suffer from significantly prolonged clearance. A slight dosage reduction may be required. • Amitriptyline, bupivacaine, clonidine, gabapentin, hydromorphone, levobupivacaine, lignocaine, methadone, mexiletine, morphine, oxycodone, and tramadol have been used in the presence of renal failure, but do require specific precautions, most frequently a significant dosage reduction. Levobupivacaine is probably safer than bupivacaine because of a higher therapeutic ratio and similar clearance mechanisms. Ropivacaine has not been studied in patients with significant renal disease 46 . • Aspirin, dextropropoxyphene, non-steroidal antiinflammatory drugs and pethidine should not be used in the presence of chronic renal failure, due to the risk of significant toxicity. In the presence of hepatic impairment, most drugs are subject to significantly impaired clearance and increased oral bioavailability, but are poorly studied in the clinical setting. The available data indicates the following:
• The agent least subject to alteration in metabolism is remifentanil; however the drug's potency limits its use to the acute care/high dependency setting. • Sufentanil clearance is unlikely to be impaired with uncomplicated mild cirrhosis.
• Tramadol may be given at lower doses, as per product guidelines, with lesser degrees of hepatic impairment. • Methadone is contraindicated in the presence of severe liver disease due to the potential for greatly prolonged clearance. • Local anaesthetic clearance may be impaired to quite significant degrees, and all types must be administered cautiously in decreased doses. The two newer agents; ropivacaine and levobupivacaine, may be safer than bupivacaine due to a higher therapeutic index, but have not been studied in this context 46, 47 . • Amitriptyline, carbamazepine and valproate use should be avoided as the risk of fulminant hepatic failure is higher in this population. • NSAIDs are subject to decreased clearance and an increased risk of causing renal failure. If used, the dose must be decreased in accordance with product guidelines. • Paracetamol may unpredictably accumulate and lead to hepatic necrosis. It has been used in the presence of mild cirrhosis, and should be associated with regular monitoring of hepatic function in this situation. It should be avoided in greater degrees of hepatic impairment. • No evidence was found using the search protocol to guide treatment using other agents.
